<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02001610</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201300549</org_study_id>
    <secondary_id>PS Project 00090915</secondary_id>
    <nct_id>NCT02001610</nct_id>
  </id_info>
  <brief_title>Acidophilus Pearls Fecal Recovery Study</brief_title>
  <official_title>Clinical Trial of the Viability of LAB and Bifidobacteria From Acidophilus Pearls in Human Stool Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schwabe North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Commercial probiotics can be delivered in numerous forms. The two most common delivery forms&#xD;
      are similar to the two product formats to be tested. It has been demonstrated using in vitro&#xD;
      testing that probiotic organisms that are unprotected from gastric exposure may not survive&#xD;
      that exposure and therefore may not remain viable throughout the rest of the GIT.&#xD;
      (Unpublished studies conducted at SNA research facility, February, 2010.) Similar in vitro&#xD;
      testing of Acidophilus Pearls has demonstrated the probiotic organisms in an enteric capsule&#xD;
      will survive gastric exposure. It is anticipated that this difference in in vitro gastric&#xD;
      survivability will translate to improved digestive tract survivability that can be&#xD;
      demonstrated using fecal recovery techniques.&#xD;
&#xD;
      The commercial product to be tested in this clinical trial has been in the market for over 17&#xD;
      years. However, it is not known what effect this commercial product has on the commensal&#xD;
      probiotic population in the gut and particularly in the lower bowel where much of probiotic&#xD;
      benefits are believed to be largely realized. Also, it is not known what effect the&#xD;
      commercial product has on the total commensal microbiota or fecal pH. While commercial&#xD;
      probiotic products have been largely aimed at benefits related to improved health, they also&#xD;
      have the potential to change overall gut microbiota (probiotics as well as all others)&#xD;
      composition and activities. Learning what happens to the overall gut microbiota can be a&#xD;
      helpful step in establishing the potential health benefits of the probiotic class of&#xD;
      organisms in the test products.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in fecal survival of probiotics</measure>
    <time_frame>Day 0 (before start of intervention), Day5-7 , Day 10-12 (end of intervention) and Day 17-19</time_frame>
    <description>The investigators will measure survival of the probiotics in fecal samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GI symptoms</measure>
    <time_frame>Day 7-9 and day 10-12</time_frame>
    <description>Change in GI symptoms using a weekly questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fecal markers</measure>
    <time_frame>Day 0 (before start of intervention), Day5-7 , Day 10-12 (end of intervention) and Day 17-19</time_frame>
    <description>The investigators will measure fecal markers. This includes stool consistency on Bristol scale and pH.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Survival of Probiotics During GI Transit</condition>
  <condition>GI Symptoms</condition>
  <arm_group>
    <arm_group_label>Hard shell gelatin capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison delivery vehicle in the form of gelatin capsule&#xD;
One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acidophilus pearls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Encapsulated using patented process&#xD;
One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Acidophilus pearls</intervention_name>
    <description>Acidophilus pearls are encapsulated using patented process&#xD;
Subjects take one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days</description>
    <arm_group_label>Acidophilus pearls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hard shell gelatin capsules</intervention_name>
    <description>Hard-shelled gelatin capsule with same microbial formulation as pearl supplement&#xD;
Subjects consume one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days</description>
    <arm_group_label>Hard shell gelatin capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult&#xD;
&#xD;
          -  Regular and predictable bowel movement pattern&#xD;
&#xD;
          -  Willing to disclose OTC/prescription medications and dietary supplements taken during&#xD;
             the study&#xD;
&#xD;
          -  Willing to sign comprehensive informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Digestive disorders&#xD;
&#xD;
          -  Use of prescribed medications that affect bowel function or microbiota (antibiotics,&#xD;
             pain medications, laxatives)&#xD;
&#xD;
          -  Use of dietary supplements/foods that can affect bowel function or microbiota&#xD;
&#xD;
          -  Excessive alcohol use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Mai, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emerging Pathogens Institute</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiota</keyword>
  <keyword>probiotics</keyword>
  <keyword>fecal markers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

